EcoSynthetix Valuation
Is 0Y8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Y8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Y8 (€2.58) is trading above our estimate of fair value (€0.56)
Significantly Below Fair Value: 0Y8 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Y8?
Key metric: As 0Y8 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0Y8's PS Ratio? | |
|---|---|
| PS Ratio | 10.7x |
| Sales | US$15.95m |
| Market Cap | US$170.67m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.7x |
| Enterprise Value/EBITDA | -39.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0Y8's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
2HRA H&R GmbH KGaA | 0.1x | 3.0% | €127.3m |
NTG Nabaltec | 0.6x | 5.1% | €123.6m |
UZU Uzin Utz | 0.5x | 4.3% | €250.2m |
BNN BRAIN Biotech | 1.2x | 8.5% | €68.8m |
0Y8 EcoSynthetix | 10.7x | n/a | €238.6m |
Price-To-Sales vs Peers: 0Y8 is expensive based on its Price-To-Sales Ratio (10.7x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does 0Y8's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 0Y8 is expensive based on its Price-To-Sales Ratio (10.7x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 0Y8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0Y8's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.1b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.70
7D
0%
1Y
41.0%
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.91
7D
4.9%
1Y
-15.5%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-4.4%
1Y
-19.9%